Takeda unveils secondary endpoint data from Phase III PsO pill trials
The key secondary endpoints found the PsO pill to be beneficial in high-impact areas, including the scalp, palms, and soles.
17 July 2026
17 July 2026
The key secondary endpoints found the PsO pill to be beneficial in high-impact areas, including the scalp, palms, and soles.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.